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Abstract In the last twenty years, one of the main goals in the drug discovery field has been the development 
of reliable in vitro models. In particular, in 2006 the European Centre for the Validation of Alternative 
Methods (ECVAM) has approved the Colony forming Unit-Granulocytes-Macrophages (CFU-GM) test, 
which is the first and currently unique test applied to evaluate the myelotoxicity of xenobiotics in vitro. The 
present work aimed at miniaturizing this in vitro assay by developing and validating a Lab-on-Chip (LoC) 
platform consisting of a high number of bioreactor chambers with screening capabilities in a high-throughput 
regime. 
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1. Introduction 
 
 In the last twenty years, one of the main 
goals in the drug discovery field has been the 
development of reliable in vitro models. To 
approve new drugs it is currently necessary to 
perform in vivo studies including at least two 
animal species and require employment of 
various dosing schedules, depending on the 
molecule to be approved (Boorman et al., 
1982). Recent research has been focusing on 
the development of new platforms able to 
replace, or reduce, the traditional in vivo trials 
at least for the early stages of the drug 
discovery process. Advantages of the in vitro 
approach mainly rely on economical and 
ethical standpoints. Indeed, in vitro testing 
presents numerous advantages, namely the 
reduction of model-to-model variability, ease 
of data collection, less requirements in terms 
of personnel training, reduction in the amounts 
of reagents, miniaturization and automation 
(Hartung and Daston, 2009). 
One of the fields which could mainly benefit 
from the paradigm shift towards in vitro 
experimentation is toxicology, i.e. the study of 
drug toxicity (Gad, 1990). In particular, 
clonogenic assays are thought to better bridge 
the gap between toxicity experienced in vivo 
and toxicity effects on cells cultivated in the 
laboratory (cytotoxicity). Clonogenic assays 
are cytotoxicity tests based on the rate of 
survival of colony forming units (CFUs) in the 
presence of several drug concentrations, thus 
differing from traditional proliferation assays 
which take into account the mere increase in 
cell number. Specific advantages of 
clonogenic assays are related to higher 
accuracy and predictivity with respect to 
traditional proliferation tests (Pessina et al., 
2004). 
To date, the European Centre for Validation of 
Alternative Methods (ECVAM) has approved 
only one clonogenic test (DB-ALM protocol 
101, available on http://ecvam-
dbalm.jrc.ec.europa.eu/). This particular test 
aims at characterizing the acute effect of 
toxicants on granulocytes and macrophages 
(GM) progenitor cells derived both from bone 
marrow and umbilical cord blood, under 
maximally stimulatory cytokine 
concentrations. The system is based on 
counting CFUs formed by the surviving 
progenitors after xenobiotics exposure.  
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In 2004 Pessina and co-workers optimized a 
new protocol for CFU-GM assay based on the 
use of 96-well plates in place of standard Petri 
dishes thus reducing complexity and costs of 
the original test. 
However, the assay still remains time-
consuming. Colonies are generally counted 
only upon 14 days of incubation. In addition, 
the assay implies the dispersion of cells within 
a semisolid culture medium, which inhibits a 
pre-determined localization of colonies (within 
dishes or wells), which all must be manually 
found by a trained operator (Pessina et al., 
2001). 
Our goal was to develop a microfluidic device 
able to miniaturize the current state-of-art 
paradigm of in vitro hematotoxicity of 
xenobiotics protocol. Indeed, a further 
miniaturization of the original assay, down to 
the micrometer scale, will provide at the same 
time advantages in terms of cost reduction 
(cells, drugs, cytokines, etc.) and decrease of 
testing time (colony forming process). To this 
aim we designed a novel Lab-on-Chip (LoC) 
platform enabling for trapping, feeding and 
growing of multipotent monoclonal stem cells. 
 
2. Materials and Methods 
 
2.1 Lab-on-Chip design and fabrication 
 A grid-like distribution of micro-chambers 
was envisaged within the LoC device to 
organize the spatial distribution of cells and, in 
turn, to obtain a univocal correspondence 
between colonies and culture chambers. 
For this purpose we designed a microfluidic 
platform divided in two functional areas: a 
serial dilution generator (Jeon et al., 2002; 
Kim et al., 2008; Lee et al., 2009) and a 
culture region (Fig. 1). The first one consists 
of a collection of channels (70µm high and 
70µm wide) arranged in a resistive flow-based 
scheme to generate six linear dilutions of 
drugs (concentration ranging from 1 to 0, step 
0.2) from two input ports to the culture region. 
This area is useful to evaluate the maximum 
tolerated dose of drugs on bone marrow 
progenitor cells.  
Downstream, the culture region consists of 
180 cubic chambers (side 150µm) divided in 6 
units, each composed by 3 lines of ten culture 
chambers. 
The microfluidic device is made of 
polydimethylsiloxane (PDMS) by means of 
standard soft lithography techniques. Briefly, a 
4” (~10cm) silicon wafer, microstructured 
with two photoresist types, served as master 
mold to cast a thin layer (about 1mm) of liquid 
PDMS, being curing agent and pre-polymer 
mixed in a ratio 1:10 (w/w). A 3 hours thermal 
treatment in an oven at 65°C was applied to 
achieve a complete crosslinking. 
Subsequently, the cured PDMS stamp was 
removed from the mold and bonded, upon an 
air plasma treatment, to a previously casted 
slab of PDMS (thickness 4 mm) to close the 
fluidic features. The assembly was trimmed 
and drilled in correspondence of 4 inputs and 6 
outputs, by means of biopsy punchers having 
diameters of 0.5 and 3mm, respectively. 
Finally, the LoC device was bonded to a 
histology glass slide upon a further air plasma 
treatment, sterilized through autoclaving 
(121°C, 20 min, wet cycle) and subsequently 
dried overnight at 80°C to recover PDMS 
hydrophobicity after plasma treatment, thus 
minimizing cell adhesion. 
 
 
Fig. 1. The layout of the Lab-on-Chip device is 
shown together with a detail of a group of 
chambers within a culture unit. Two main input 
ports (together with two secondary ports) deliver 
dilutions of chemicals (100%, 80%, 60%, 40%, 
20%, CTRL) to 6 culture units (30 chambers each). 
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2.2 Cell expansion and characterization 
 As a source of stem cells, the 
mononucleated cell fraction from human 
umbilical cord blood (CB-MNCs) purchased 
frozen from Lonza (Switzerland) was used.  
The cells, stored in liquid nitrogen until use, 
were thawed according to a previously 
described standard operating procedure 
(Pessina et al., 2004). Briefly, thawed cells 
were transferred from the cryovial to a 15 ml 
conical tube and swirled while warmed 
thawing medium (Iscove’s Modified Dulbecco 
Medium (IMDM) supplemented with 10% 
Fetal Bovine Serum (FBS) and 10 U/ml Dnase 
I) was added drop by drop to the cells. The cell 
suspension was then centrifuged at 200g for 15 
min at room temperature. 
Most of the wash was removed by pipette 
leaving 1–2 ml behind so the cell pellet was 
not disturbed and was then resuspended in the 
remaining medium. Fresh IMDM with 1% l-
glutamine and 10% FBS was added to the cell 
suspension and then centrifuged as above 
described. All the reagents were purchased 
from EuroClone (Italy). Cells were then 
resuspended in Complete Medium (CM), 
consisting of IMDM, containing 30% FBS, 1% 
L-Glutamine, 1% Penicillin/Streptomycin 
solution and 10 ng/ml recombinant human 
granulocyte/ macrophage colony-stimulating 
factor (r hu GM-CSF, RELIATech, Germany) 
to evaluate their number and viability.  
Subsequently, CFU based tests were 
performed by using pooled donor cord blood-
derived CD34+ cells, purchased frozen from 
Life Technologies, USA. The cells were stored 
and thawed according to the same protocol 
applied for CB-MNCs. 
 
2.3 Cell seeding within the LoC platform 
 Preliminary tests were carried out to 
establish a correlation between cell seeding 
conditions and number of cells trapped in each 
chamber. For this purpose CB MNCs were 
used. Aliquots of 30µl of cell suspension 
(concentration of 500,000 cells/ml) were 
simultaneously injected into both input ports 
through a dual channel syringe pump at a flow 
rate of either 0.1 or 0.2 µl/min. Upon complete 
seeding, a picture of each chamber was taken 
through a phase contrast microscope, and the 
number of cells contained in each chamber 
was directly quantified. For these experiments, 
a number of 9 and 8 replicates (n=9 and n=8) 
were used for 0.1 and 0.2µl/min, respectively. 
 
 
Fig. 2. Content in terms of cell number for each of 
the 10 chambers encountered by cells in their 
stream. Each device has 18 decades of chambers, 
and experiments were carried out for 9 and 8 
replicates for 0.1 and 0.2 µl/min flow rates, 
respectively. Data is presented as mean ± standard 
deviation.  
 
The cell distribution for both conditions tested 
is depicted in Fig. 2, which shows a decrement 
in population along chambers in the same 
fluidic path. In particular, the number of cells 
present in each chamber at the end of the 
seeding process resulted 14.2 ± 26.2 and 16.8 
± 18.7 for flow rates of 0.1 and 0.2µl/min, 
respectively. Although these values were 
similar, the higher flow rate provided a 
significantly lower number of empty chambers 
(24.4 ± 22.8 vs 11.4 ± 9.5), while reducing the 
seeding time (2.5 vs 5 hours). Thus 0.2 µl/min 
was chosen as seeding condition for the 
following experiments and corresponding data 
was used in the statistical model. 
 
2.4 Statistical model of the clonogenic assay 
 In general, the toxicity effect of a drug 
molecule tested through a clonogenic assay 
shows up through a smaller number of CFUs 
with respect to a control condition wherein no 
drug is administered. For a suitable statistical 
analysis, we modeled this situation as if the 
drug was able to decrease the probability of 
any single cell to be clonogenic, while keeping 
the number of cells constant. 
We denote with p0 the probability of any cell 
to form a colony in the control. According to 
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the results obtained with standard macroscale 
experiments, in our case study p0 was set equal 
to 1/146. We then set a hypothesis test to 
determine if there is statistical evidence to 
state whether the probability p of a cell to 
form a colony when drug is administered is 
smaller than the probability p0 in the control. 
Hence, in the null hypothesis we have p=p0, 
while in the alternative hypothesis we have 
p=p1<p0. 
The seeding process suggested us to model the 
number of cells injected in each chamber as a 
random variable with a probability distribution 
depending on the position of the chamber in 
the corresponding line. Moreover, all the 
chambers in the chip were treated as 
independent variables, and all the lines and 
units were considered to have the same 
distribution of cells. From the data collected in 
the seeding characterization tests (Fig. 2, 
perfusion rate 0.2µl/min) we computed the 
empirical distribution of the number of cells 
for each position within the culture line 
(constituted by 10 chambers). 
The probability to find a colony in each 
chamber was obtained by modelling the 
number of clonogenic cells per chamber with a 
binomial law, having the same number as the 
average number of cells in that chamber and 
probability equal to p0. Then, the distribution 
of positive chambers (chambers+, i.e., 
chambers containing at least one colony) was 
computed for a chip with n chambers (or n/10 
culture lines). Simulations were run through 
the R environment (software version 2.13.1), 
and a set of 10000 repetitions was enough to 
obtain stable distributions. 
A critical region for the hypothesis test was 
built as follows: the null hypothesis (i.e. a cell 
is clonogenic with a probability equal to p0) 
has to be rejected whenever the number of 
chambers+ in the chip is less than a threshold 
C. The threshold value depends upon the 
significance level α of the test and the number 
of chambers in the chip n. For instance, by 
setting α=0.05, in our chip (n=180) we 
obtained C=12. 
Furthermore, we computed the power of the 
test for different values of p1, that is the 
probability of having less than C chambers+ 
due to the effect of the administered drug 
(p1<p0). In Fig. 3, for instance, we show the 
probability distribution of the chambers+ for a 
particular choice of p1 = 1/2p0 = 1/292, 
corresponding to the ideal IC50 for a drug 
molecule. In this case, the power resulted 
equal to 73.8%. 
 
 
 
 
Fig. 3. Probability distributions of the number of 
chambers+ within the chip both when no drug 
(light grey; probability of proliferation p0=1/146) 
and a drug at a concentration corresponding to the 
IC50 (dark grey; p1=1/292) are administered. The 
vertical red line indicates the threshold C=12 used 
for the critical region of the test.  
 
2.5 Implementation of the microscale 
clonogenic assay 
 CD34+ cells were seeded into the LoC 
device at a flow rate of 0.2 µl/min. Upon 2.5 
hours, CM was prepared and perfused into the 
device at the same flow rate throughout the 
entire culture period (14 days). At specific 
time points (days 1, 5, 7 and 14) pictures from 
all culture chambers of the LoC device were 
taken to monitor possible variations in cell 
number. The results were compared to control 
experiments, consisting of devices perfused 
with culture medium free from cytokines. 
CFU potential of CD34+ cells within the 
microfluidic device was also assessed in both 
conditions of absence and presence of a drug 
with a recognized hematotoxicity in clinical 
use. In particular, 1200 ng/ml (200X) of 
Paclitaxel (Toronto Research Chemicals, 
Canada) dissolved in dimethylsulfoxide 
(DMSO, Serva, Germany), were added to CM 
in order to have a final drug concentration of 6 
ng/ml and a DMSO percentage of 0.5% (v/v). 
Paclitaxel was delivered to cells through the 
input ports through continuous perfusion. The 
culture was carried up to 7 days, and pictures 
of each chamber were taken at days 1, 5 and 7. 
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Pictures from the control device were taken at 
the same time-points and used as positive 
control.  
 
3. Results and Discussion 
 
 The 2-weeks culture period within the 
microfluidic platform provided an increasing 
number of CD34+ cells in each chamber from 
day 1 to day 14 when perfused with CM, being 
the initial number of cells per chamber 13.1 ± 
15.3 and the final 24.4 ± 21.0. As shown in 
Fig. 4 the number of cells did not change 
significantly along the culture in the control 
experiment. 
 
 
Fig. 4. Increase in cell number in a period of 14 
days in culture in the LoC device. When cytokines 
are perfused together with the culture medium, the 
increase in cell number is significantly higher than 
in the case of perfusion with pure culture medium. 
 
In particular, the number of cells had an 
increase from day 1 to day 5 (21.0 ± 19.0), 
thus suggesting the possibility to reduce the 
assay time by identifying the chamber 
containing colonies (positive chambers, 
chamber+) within a shorter five days period in 
vitro. 
 
 
Fig. 5. Examples of a chamber containing at least 
one CFU (top) and no CFU (bottom). 
The number of chamber+ was inferred from 
pictures for both conditions. Fig. 5 shows the 
content of two exemplifying chambers. In 
particular, a chamber was set positive in case 
the following conditions were simultaneously 
true: 
 
i. relative cell number increase > 25%; 
ii. absolute cell number increase > 4. 
 
The number of resulting chamber+ was 15.33 
± 6.11 (n=3), in agreement with the statistical 
model. 
Furthermore, as preliminary test, the number 
of chamber+ was also assessed in presence of 
Paclitaxel, a prototype toxicant molecule 
whose dosage was chosen, in agreement with 
our previous findings corresponding to half 
maximal inhibitory concentration (IC50). The 
number of chamber+ in absence of any 
toxicant substances was 14 (positive control), 
while chamber+ number was reduced to 6 
when the drug was delivered. Fig. 6 shows a 
graphical representation of the distributions of 
chamber+ (green), chamber- (yellow) and 
empty chambers (red) for both cases. 
 
 
Fig. 6. Representation of positive (green), negative 
(yellow) and empty (red) chambers. 
 
This result suggests that the device, together 
with the implemented statistical model, allows 
identifying the toxicity of a test molecule at a 
specific concentration. 
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4. Conclusions 
 
 The proposed LoC device demonstrated its 
suitability as platform for CFU-based assays. 
The average number of colonies formed after 
five days of culture (15.33 ± 6.11) was 
adequate to detect the presence of a toxic 
dosage (IC50) of a drug. The assay time was 
dramatically reduced in two ways: i) the 
culture time decreased from 14 to 5 days, and 
ii) the colony identification was reduced to 
microscopy acquisitions on a well-defined 
plane (chamber/channel fluidic layer). 
The device was provided with a serial dilution 
generator unit, able to precisely deliver to 
culture units predetermined concentration of 
soluble factors. However, the number of 
chambers implemented for these experiments 
(n=180) was only enough to catch the effect of 
a single test condition – namely the 
concentration of the administered molecule – 
and this unit was not used. Neverthless, by 
simply increasing the number of chambers 
contained in each culture unit (e.g. to 180 or 
more), the device could be exploited to fully 
implement a miniaturized clonogenic test 
directly on-chip in an automated manner. 
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